Neuphoria Therapeutics Inc.

NEUP Nasdaq SEC CIK 1191070
Follow Neuphoria Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2023 AUD · IFRS
Revenue, last year AUD 22K −91.6% vs prior year
Net income −AUD 31.8M −3586.7% vs prior year
EPS, diluted −AUD 0.02 +0% vs prior year
Operating cash flow −AUD 21.3M +1.9% vs prior year
Revenue by fiscal year
AUD 46.7K
AUD 263.6K
AUD 22K
FY20 FY22 FY23

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−AUD 40M−AUD 30M−AUD 20M−AUD 10MAUD 0AUD 10MFY19FY20FY21FY22FY23
Show the numbers
YearRevenueNet income
FY23AUD 22K−AUD 31.8M
FY22AUD 263.6KAUD 913.4K
FY21-AUD 892.5K
FY20AUD 46.7K-
FY19--
Free cash flowOperating cash flow minus capital expenditure
−AUD 30M−AUD 20M−AUD 10MAUD 0FY19FY20FY21FY22FY23
Show the numbers
YearFree cash flow
FY23-
FY22−AUD 21.8M
FY21−AUD 7.5M
FY20−AUD 3.9M
FY19-